atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

NEW YORK – atai Life Sciences a pioneering  company specializing in mental health treatment innovations, today announced the promotion of Anne Johnson to Chief Financial Officer (CFO). Johnson, who has served as the interim CFO since October 2023 and Chief Accounting Officer since August 2022, will officially succeed Stephen Bardin in the CFO role. Bardin will remain with the company in an advisory capacity through March 31, 2024, to ensure a smooth transition.

Florian Brand, Co-founder and CEO of atai, praised Johnson’s contribution and leadership within the company, highlighting her extensive experience in the biopharmaceutical sector and deep understanding of atai’s operational framework. “Anne has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence,” Brand remarked, also extending gratitude to Stephen Bardin for his significant contributions to atai’s mission.

Johnson brings nearly two decades of experience in the biotechnology and pharmaceutical industry, having held senior positions at notable companies including Aruvant Sciences, Chimerix, Inc., PPD, and Xanodyne Pharmaceuticals. She holds a Bachelor of Science in Accounting from the University of North Carolina Wilmington and is a Certified Public Accountant and Chartered Global Management Accountant.

Expressing her enthusiasm for her new role, Johnson stated, “I am honored to lead atai’s world-class finance team and am committed to strengthening our financial foundation to support our R&D programs.” She also shared her passion for atai’s mission to address mental health disorders, underscoring her dedication to advancing the development of innovative and effective treatments for patients.

Johnson’s appointment comes at a critical time for atai Life Sciences as the company continues to advance its research and development programs aimed at revolutionizing the treatment of mental health disorders.